- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Sage's string of research failures continues | ||
| Mi | Pfizer, under pressure to change, names oncology head as new R&D chief | ||
| Mi | What might a Trump administration mean for the Biosecure Act? | ||
| Mi | Chasing new 'checkpoints,' startup Valora emerges from a Nobel winner's lab | ||
| Mi | Flagship, Pfizer alliance yields two more startup deals | ||
| Di | Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says | ||
| Di | Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer | ||
| Di | J&J pill clears skin in two late-stage psoriasis studies | ||
| Di | Incyte sinks on setback for drugs acquired in $750M buyout | ||
| Mo | Syndax secures FDA OK for new kind of leukemia drug | ||
| Mo | CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest | ||
| Mo | FDA endorses speedy approval path for Regenxbio Duchenne gene therapy | ||
| Mo | Reducing variability in gene expression: bottlenecks and solutions | ||
| Mo | Leveraging NGS to move precision oncology forward, from CDx to commercialization | ||
| Fr | How a Biogen drug set the stage for a new biotech targeting ALS | ||
| Fr | 'Find any advantage': 3 biotech leaders on driving R&D success | ||
| Fr | Surviving in biotech's new normal: 5 tips from industry VCs and CEOs | ||
| Fr | Halozyme bids for Evotec; BeiGene gets a new name | ||
| 14.11. | Trump names RFK Jr. as his pick to lead HHS | ||
| 14.11. | Eisai wins over European regulators on Alzheimer's drug Leqembi | ||
| 14.11. | PTC wins US approval of gene therapy for fatal enzyme disorder | ||
| 14.11. | Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy | ||
| 13.11. | Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing | ||
| 13.11. | Metsera raises $215M to accelerate obesity drug plans | ||
| 13.11. | TRex Bio raises $84M to compete in crowded immune drug field |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
